Evidence map›Paper›PMID 33763814›Full record

ArticleAAPS PharmSciTech2021

Mirel Cabrera, Nicole Lecot, Marcelo Fernández, J P Gambini, Williams Porcal, Pablo Cabral

Abstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mirel CabreraLaboratorio de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Mataojo 2055, 11400, Montevideo, Uruguay. mcabrera@cin.edu.uy.ORCID http://orcid.org/0000-0002-5225-1106
Nicole LecotLaboratorio de ATN en Bioquímica y Biotecnología, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Mataojo 2055, 11400, Montevideo, Uruguay.
Marcelo FernándezLaboratorio de Experimentación Animal, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Mataojo 2055, 11400, Montevideo, Uruguay.
J P GambiniCentro de Medicina Nuclear, Hospital de Clínicas, Facultad de Medicina, Universidad de la Republica, Av Italia s/n, 11600, Montevideo, Uruguay.
Williams PorcalDepartamento de Química Orgánica, Facultad de Química, Universidad de la República, Av. General Flores 2124, 11800, Montevideo, Uruguay.
Pablo CabralLaboratorio de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Mataojo 2055, 11400, Montevideo, Uruguay.
Universidad de la República de Uruguay · UY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanomedicine is a highly demanded discipline. Liposomes have seen an increased attention due to their physicochemical properties that allow them to act as nanocarriers of drugs and also of radioisotopes that can be used to diagnose and treat cancer. In order to obtain a novel permeability cancer imaging agent based on

Indexed as

AnimalsCell Line, TumorLiposomesMelanoma, ExperimentalMiceMice, Inbred C57BLNiacinamidePermeabilityRadionuclide ImagingRadiopharmaceuticalsTechnetiumTissue DistributionTumor MicroenvironmentLiposomesNiacinamideRadiopharmaceuticalsTechnetium99mTccancerliposomesstearyl 6-(benzylidenehydrazinyl) nicotinamide

Identifiers

PMID33763814
OpenAlexW3137584945

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.